The next milestone was the introduction of these drugs as first-line treatment options. Subsequently, atezolizumab and pembrolizumab were also shown to be more effective than docetaxel, leading to their approval for NSCLC treatment ( 2, 3). This approval was based on the results of a phase III clinical trial that demonstrated the superiority of nivolumab compared to docetaxel in this setting ( 1). In 2015, the Food and Drug Administration approved the first ICI, nivolumab, for patients with NSCLC whose disease had progressed after platinum-based chemotherapy. This advancement has significantly changed the therapeutic approach for NSCLC patients, providing new and more effective options for disease management. Over the past decade, the treatment landscape of metastatic non-oncogene addicted non-small cell lung cancer (NSCLC) has undergone a revolutionary transformation with the emergence of immune checkpoint inhibitors (ICIs), particularly those targeting the programmed death-1 (PD-1) axis. Keywords: KEYNOTE-407 pembrolizumab non-small cell lung cancer (NSCLC) Interviews with Outstanding Guest Editors.Policy of Dealing with Allegations of Research Misconduct.Policy of Screening for Plagiarism Process.
